Format

Send to

Choose Destination
Nat Rev Drug Discov. 2002 Jul;1(7):493-502.

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.

Author information

1
Novartis Pharma AG, S-27 2.033, CH-4002 Basel, Switzerland. renaud.capdeville@pharma.novartis.com

Abstract

In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research. Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery programme was initiated with the aim of rationally developing targeted anticancer therapies. Here, we describe how this programme led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.

PMID:
12120256
DOI:
10.1038/nrd839
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center